APA (7th ed.) Citation

O, S., M, A., & A, P. (2025). In vitro susceptibility of clinical Clostridioides difficile isolates in Israel to metronidazole, vancomycin, fidaxomicin, ridinilazole and ibezapolstat. BMC gastroenterology, 25(1), 209. https://doi.org/10.1186/s12876-025-03800-7

Chicago Style (17th ed.) Citation

O, Schwartz, Azrad M, and Peretz A. "In Vitro Susceptibility of Clinical Clostridioides Difficile Isolates in Israel to Metronidazole, Vancomycin, Fidaxomicin, Ridinilazole and Ibezapolstat." BMC Gastroenterology 25, no. 1 (2025): 209. https://doi.org/10.1186/s12876-025-03800-7.

MLA (9th ed.) Citation

O, Schwartz, et al. "In Vitro Susceptibility of Clinical Clostridioides Difficile Isolates in Israel to Metronidazole, Vancomycin, Fidaxomicin, Ridinilazole and Ibezapolstat." BMC Gastroenterology, vol. 25, no. 1, 2025, p. 209, https://doi.org/10.1186/s12876-025-03800-7.